▲ +0.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Urovant Sciences in the last 3 months. The average price target is $16.17, with a high forecast of $16.25 and a low forecast of $16.00. The average price target represents a 0.60% upside from the last price of $16.07.
The current consensus among 3 contributing investment analysts is to hold stock in Urovant Sciences. This Hold consensus rating has held steady for over two years.
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.